NewsRoom Articles

WednesdayMar 18, 2026 10:00 am

Scientists Discover Why Colon Cancer Diagnoses are Increasing in Young Adults

Researchers have found that people under 50 who develop colorectal cancer have unusually rigid colon tissue that helps tumors grow, offering the first clear explanation for rising cancer rates in younger adults. A University of Texas at Dallas team working with UT Southwestern Medical Center discovered that both tumor samples and surrounding healthy tissue were mechanically stiffer in younger patients than in older people with the same disease. Physical tissue properties appear to drive early-onset colorectal cancer, which has become the top cancer killer among Americans under 50. UT Dallas bioengineering Assistant Professor Jacopo Ferruzzi says this marks the first study showing how mechanical forces contribute to…

MondayMar 16, 2026 10:00 am

US Military Admits it is Using AI in Attacks Against Iran

The U.S. military has confirmed that AI systems are actively involved in its ongoing operations against Iran, an admission that has added significant fuel to an international debate that was already running hot. Brad Cooper, commander of U.S. Central Command, outlined the role of artificial intelligence systems in a publicly released video. He positioned AI as critical infrastructure for processing the enormous volumes of information that flow through a modern military campaign. Cooper was explicit that the technology shapes the conditions in which decisions are made. It compresses analysis that once took many hours into something commanders can act on almost immediately. He also said that human judgment is…

MondayMar 16, 2026 9:45 am

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer. LIXTE develops LB-100, a drug that enhances the effectiveness of cancer treatments, while Liora has developed a unique cancer treatment that’s believed to be more affordable, precise, and efficient than many traditional options. Together, this pair of products have incredible clinical and commercial potential, to both help the businesses succeed, while also offering better outcomes for patients suffering from cancer. LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined,…

FridayMar 13, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and GSK The company operates at the nexus of targeted cancer biology and combination therapy innovation These partnerships help underscore LIXTE’s broader strategy: enhancing established cancer treatments through its first-in-class compound LB 100 LIXTE Biotechnology Holdings (NASDAQ: LIXT) continues to promote its lead oncology asset, LB 100, through a partnership-driven model designed to accelerate development and improve scientific validation. Recently, the company announced the expansion of its ongoing clinical collaboration with the University of Texas MD Anderson Cancer Center and GSK plc to evaluate LB 100…

WednesdayMar 11, 2026 10:00 am

Researchers Trace Differing Pediatric Brain Tumors to Common Source

New research has uncovered a shared biological weakness running across three distinct pediatric brain cancers, a finding that opens a realistic path toward therapies capable of targeting all three at once. The discovery grew out of a deep dive into one of the rarest childhood tumors on record and ended up revealing far more than anyone initially set out to find. Pineoblastoma originates in the pineal gland, a small structure at the brain's core responsible for producing hormones, including melatonin. Cases are rare enough that most specialized pediatric oncology programs handle only a small number each year. Pooling resources across three institutions, St. Jude Children's Research…

MondayMar 09, 2026 3:24 pm

Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy

LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy. Specifically,…

MondayMar 09, 2026 10:00 am

Ongoing Digital Monitoring Could Make Immunotherapy More Accessible

Ongoing digital monitoring could be about to solve one of modern medicine's most frustrating access problems. Life-extending cancer immunotherapies exist and there are numerous patients who could benefit from such therapies, but a mandatory hospital stay requirement currently makes access to immunotherapy nigh impossible for rural and underserved patients. However, a growing body of evidence now suggests that continuous remote monitoring could remove the need for hospital stays post immunotherapy. CAR-T cell therapies and related immunotherapies have reshaped what is possible for patients with certain blood cancers, producing remission rates that were unthinkable a generation ago. Thirteen of these treatments now carry FDA approval across two therapy categories. Getting them to patients,…

MondayMar 09, 2026 9:00 am

Frontieras North America Inc. Is ‘One to Watch’

Frontieras’ patent portfolio includes protection across five continents and nine countries, covering approximately 85% of global coal production. The FASForm(TM) process is designed as a closed-loop, zero-waste system that converts coal into multiple market-ready energy and industrial products. Long-term feedstock and product offtake frameworks are in place for the company’s flagship commercial facility. The Mason County project is structured as a large-scale infrastructure development with established engineering, construction, operations, logistics, and insurance partners. Frontieras’ commercialization strategy focuses on replicable facilities serving established energy and chemicals markets with existing demand. Frontieras North America is an energy and environmental technology company focused…

FridayMar 06, 2026 11:15 am

GridAI Technologies Corp. (NASDAQ: GRDX) Is Capitalizing on the Data Center and AI-Driven Transformation of the Energy Sector

AI data centers are rapidly increasing electricity consumption, creating new and significant pressures on America’s power infrastructure, with analysts warning that reliable electricity supply could become a defining constraint in global AI competition. Large AI facilities require integrated control of multiple energy assets and market inputs, with real-time monitoring and analytics becoming essential to the management of complex energy systems supporting AI infrastructure. GridAI is developing software to coordinate grid power, on-site generation, battery storage and backup systems for AI data-center campuses. Artificial intelligence has triggered a global race for computing capacity, but a serious bottleneck is beginning to emerge:…

FridayMar 06, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents The company is advancing LB-100 through clinical development in collaboration with academic and research institutions Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000